Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: Identification of candidates for clinical development

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4339-4344

  McClure, Kim F ^a   Letavic, Michael A ^a   Kalgutkar, Amit S ^a   Gabel, Christopher A ^a   Audoly, Laurent ^a   Barberia, John T ^a   Braganza, John F ^a   Carter, Demetrius ^a   Carty, Thomas J ^a   Cortina, Santo R ^a   Dombroski, Mark A ^a   Donahue, Kathleen M ^a   Elliott, Nancy C ^a   Gibbons, Colleen P ^a   Jordan, Crystal K ^a   Kuperman, Alexander V ^a   Labasi, Jeff M ^a   LaLiberte, Ronald E ^a   McCoy, Jennifer M ^a   Naiman, Brian M ^a   Nelson, Kendra L ^a   Nguyen, Hang T ^a   Peese, Kevin M ^a   Sweeney, Francis J ^a   Taylor, Timothy J ^a   Trebino, Catherine E ^a   Abramov, Yuriy A ^a   Laird, Ellen R ^a   Volberg, Walter A ^a   Zhou, Jun ^a   Bach, Justin ^a   Lombardo, Franco ^a   more..

^a PFIZER INC   (United States)

Author keywords

Anti inflammatory; Arthritis; Clinical candidate; CP 808844; Cytokine; Inflammation; Inhibitor; MAP; mitogen activated protein; Oxazole; p38 kinase; SAR; structure activity relationship; TNF ; Triazole; Triazolopyridine; tumor necrosis factor

Indexed keywords

CP 808844; OXAZOLE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN P38 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; OXAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 33745699202     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.056     Document Type: Article

References (25)

1. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., et al. Nature 372 (1994) 739
2. Dominguez C., Tamayo N., and Zhang D. Expert Opin. Ther. Patents 15 (2005) 801
3. Fijen J.W., Zijlstra J.G., De Boer P., Spanjersberg R., Cohen Tervaert J.W., Van Der Werf T.S., Ligtenberg J.J., and Tulleken J.E. Clin. Exp. Immunol. 124 (2001) 16
4. Kim A.L., Labasi J.M., Zhu Y., Tang X., McClure K., Gabel C.A., Athar M., and Bickers D.R. J. Invest. Dermatol. 124 (2005) 1318
5. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., and Gaestel M. Nat. Cell Biol. 1 (1999) 94
6. 2 for 4 h. Plasma was assessed for TNF-α by ELISA (R&D Systems).
7. Boehm J.C., Smietana J.M., Sorenson M.E., Garigipati R.S., Gallagher T.F., Sheldrake P.L., Bradbeer J., Badger A.M., Laydon J.T., Lee J.C., Hillegass L.M., Griswold D.E., Breton J.J., Chabot-Fletcher M.C., and Adams J.L. J. Med. Chem. 39 (1996) 3929
8. Badger A.M., Griswold D.E., Kapadia R., Blake S., Swift B.A., Hoffman S.J., Stroup G.B., Webb E., Rieman D.J., Gowen M., Boehm J.C., Adams J.L., and Lee J.C. Arthritis Rheum. 43 (2000) 175
9. Henry J.R., Rupert K.C., Dodd J.H., Turchi I.J., Wadsworth S.A., Cavender D.E., Schafer P.H., and Siekierka J.J. Bioorg. Med. Chem. Lett. 8 (1998) 3335
10. Henry J.R., Rupert K.C., Dodd J.H., Turchi I.J., Wadsworth S.A., Cavender D.E., Fahmy B., Olini G.C., Davis J.E., Pellegrino-Gensey J.L., Schafer P.H., and Siekierka J.J. J. Med. Chem. 41 (1998) 4196
11. Haddad J.J. Curr. Opin. Investig. Drugs 2 (2001) 1070
12. 50s were determined as described in:. Dombroski M.A., Letavic M.A., McClure K.F., Barberia J.T., Carty T.J., Cortina S.R., Csiki C., Dipesa A.J., Elliott N.C., Gabel C.A., Jordan C.K., Labasi J.M., Martin W.H., Peese K.M., Stock I.A., Svensson L., Sweeney F.J., and Yu C.H. Bioorg. Med. Chem. Lett. 14 (2004) 919
13. McClure K.F., Abramov Y.A., Laird E.R., Barberia J.T., Cai W., Carty T.J., Cortina S.R., Danley D.E., Dipesa A.J., Donahue K.M., Dombroski M.A., Elliott N.C., Gabel C.A., Han S., Hynes T.R., LeMotte P.K., Mansour M.N., Marr E.S., Letavic M.A., Pandit J., Ripin D.B., Sweeney F.J., Tan D., and Tao Y. J. Med. Chem. 48 (2005) 5728
14. 50s > 10 μM against the following kinases: p38γ, p38δ, MKK1, MAPK2/ERK2, JNK, MAPKAP-K1a, MAPKAP-K2, MSK1, PRAK, PKA, PKCα, PDK1, PKBα, SGK, P70S6K, GSK3β, ROCK-II, AMPK, CHK1, CK2, Lck, CSK, CDK2, PI3-K, DYRK1a, PHOS. Kinase.
15. All procedures were reviewed and approved by the Institutional Animal Care & Use Committee.
16. 2 and bled by cardiac puncture. Blood was collected in Vaccutainer tubes and spun for 20 min at 3000 rpm. Serum was assayed for TNF-α levels using an ELISA (R& D Systems).
17. Kalgutkar, A. S.; Hatch, H. L.; Kosea, F.; McClure, K. F.; Dombroski, M. A.; Choo, E. F.; Henne, K. R.; Taylor, T. J.; Kuperman, A. V. Boopharm. Drug Dispos. Manusscript in press.
18. PDB accession code 1ZZL.
19. 2. After 4 h, cell supernatants were harvested by centrifugation and TNF-α concentration determined by ELISA (R&D).
20. Davies I.W., Marcoux J.F., Corley E.G., Journet M., Cai D.W., Palucki M., Wu J., Larsen R.D., Rossen K., Pye P.J., DiMichele L., Dormer P., and Reider P.J. J. Org. Chem. 65 (2000) 8415
21. Shih N.-Y. Tetrahedron Lett. 34 (1993) 595
22. Sisko J., Kassick A.J., Mellinger M., Filan J.J., Allen A., and Olsen M.A. J. Org. Chem. 65 (2000) 1516
23. Volberg W.A., Koci B.J., Su W., Lin J., and Zhou J. J. Pharmacol. Exp. Ther. 302 (2002) 320
24. Sinnokrot M.O., and Sherrill C.D. J. Am. Chem. Soc. 126 (2004) 7690
25. Sanchez-Chapula J.A., Navarro-Polanco R.A., Culberson C., Chen J., and Sanguinetti M.C. J. Biol. Chem. 277 (2002) 23587